DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2007/0042030 A1 Cevc (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2007/0042030 A1 Cevc (43) Pub US 20070042030A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0042030 A1 Cevc (43) Pub. Date: Feb. 22, 2007 (54) PREPARATION FOR THE APPLICATION OF Mar. 6, 1991 (DE).............................................. 4107 153 AGENTS IN MINI-DROPLETS Mar. 6, 1991 (DE).............................................. 4107 152 Aug. 22, 1991 (WO)........................... PCT/EP91/O1596 (75) Inventor: Gregor Cevc, Heinstetten (DE) Publication Classification Correspondence Address: EDWARDS & ANGELL, LLP (51) Int. Cl. P.O. BOX SS874 A 6LX 9/27 (2006.01) BOSTON, MA 02205 (US) (52) U.S. Cl. ............................................ 424/450; 977/907 (73) Assignee: IDEA AG, Munchen (DE) (57) ABSTRACT (21) Appl. No.: 11/481,804 The invention relates to a preparation for the application of 1-1. agents in the form of minuscule droplets of fluid, in par (22) Filed: Jul. 5, 2006 ticular provided with membrane-like structures consisting of Related U.S. Application Data one or several layers of amphiphilic molecules, or an AV amphiphilic carrier Substance, in particular for transporting (63) Continuation of application No. 09/621,574, filed on the agent into and through natural barriers such as skin and Jul. 21, 2000, which is a continuation of application similar materials. The preparation contains a concentration No. 07/844 644 filed on Apr. 23, 1992, now aban- of edge active substances which amounts to up to 99 mol-% doned. sy is s s of the agent concentration which is required for the induc tion of droplet solubilization. Such preparations are suitable, (30) Foreign Application Priority Data for example, for the non-invasive applications of antidia betics, in particular of insulin. The invention, moreover, Aug. 24, 1990 (DE).............................................. 4O26833 relates to the methods for the preparation of such formula Aug. 24, 1990 (DE).............................................. 4O26834 tions. 12 600 MEANSIZE 10 500 e S as y 400 e Éf 5 g 300 S o 2 3E sc d in M 200 l s s ? 100 O 1 2 3 4 O 1 2 3 4. S100/OAC (mol/mol) Patent Application Publication Feb. 22, 2007 Sheet 1 of 21 US 2007/0042030 A1 s XX as O E S Co o O O O O o 9 O O Co O O O S CO tr cy CN ver Nee s Sn S2 3ONWISIS (+) Ha Patent Application Publication Feb. 22, 2007 Sheet 2 of 21 US 2007/0042030 A1 C s N 2 a. s 2 S 8 S. 8 S. S. S. C as CN co r cr) N y Ye CD (uu) aWWIO s l O as S2 CMO N C/O 2 C l d o o o O o o O Cd o O O Co C CO O r cr) cN w (uuu) LWWIO Patent Application Publication Feb. 22, 2007 Sheet 3 of 21 US 2007/0042030 A1 N CO Z CC as -- H ---- 1S - S o o O Co o O as g S. S S S2 5 CY (uu). NOLIVIAO OWONWLS "YLWWIOf O U 3. o CC 9 CD l 8 o SN Se CO CO s C O ONWISIS32 (+)Hd Patent Application Publication Feb. 22, 2007 Sheet 5 of 21 US 2007/0042030 A1 N CVO 2 CC O d as O E ar s o o O o O o 9 o o O O O S r cr) cN were uu) NOLIVIAOO-VONVLS' 3.13WVIO s ONWISIS Patent Application Publication Feb. 22, 2007 Sheet 6 of 21 US 2007/0042030 A1 N CfO 2. CC U s S. i S 8 s(uu) NOLIVIAOO&WONWLS5 & "WWI8 & S. - U H is O O Vs a 8 o SN S2 o co r on O 3ONVISISY "(...)Hd Patent Application Publication Feb. 22, 2007 Sheet 7 of 21 US 2007/0042030 A1 O vs. OO g N to is 5 CD c C CD - 5(5. l ? CN O ve O 2 CS NOILWW&O IOISA-OW Patent Application Publication Feb. 22, 2007 Sheet 8 of 21 US 2007/0042030 A1 Co qs g R CVO 2 n CC 2 s <CL s as . E Co S o C - co C o c. 9 D O l) O O E (uu) LWWIO g ONWISISR Patent Application Publication Feb. 22, 2007 Sheet 9 of 21 US 2007/0042030 A1 O as S a (uu) NOLIVIN3Os OVONVIS'y5 & 13WVIO 8 & U L - C C/O O O CD - CD 9. S o ONWISIS Patent Application Publication Feb. 22, 2007 Sheet 10 of 21 US 2007/0042030 A1 | t SNN 22 N 2 III 2 s s III 2 S (%)XWildn NIXIS Patent Application Publication Feb. 22, 2007 Sheet 11 of 21 US 2007/0042030 A1 e (%) OOO19 NISOO Patent Application Publication Feb. 22, 2007 Sheet 12 of 21 US 2007/0042030 A1 CfO s O CO 1. CO5 H CN q O (%)OOO19 NISOO Patent Application Publication Feb. 22, 2007 Sheet 13 of 21 US 2007/0042030 A1 : s3. s s s C O L O ld s vs v s CP/5u) OOOTNINOIL3 id3O3SOOn 19 Patent Application Publication Feb. 22, 2007 Sheet 14 of 21 US 2007/0042030 A1 U N CMO Z CC d s O S S Cd Co Co O O o S2 C Cd C O O S r cyd CN v aua WN CD OdO sa : l nal O C v CO L CO C . Cl co fa d E N. ONWISIS Patent Application Publication Feb. 22, 2007 Sheet 15 of 21 US 2007/0042030 A1 O N Z CC ; s S o O 92 o o lc) d S. S 5 \ (uu) NOILWINO OWONWLS "YLWWIO S. U o stS. e 3 do ONWISISS Patent Application Publication Feb. 22, 2007 Sheet 16 of 21 US 2007/0042030 A1 o r D cy O cr) 2 O e es C C Lo 9 CVO O CS S n1 s O s s S. vs. D S Co • C CN Co CD CO On 2 to 8 ve CVO Z O S2 CAP S O O CO O LO O v- O O CN N. cs CN ve O O (uu OOv) OO Patent Application Publication Feb. 22, 2007 Sheet 17 of 21 US 2007/0042030 A1 g 2 - D CVO 2 s s 2 CC 4 ? s O N1 n1 S O d O O s S2 ve g (IP/5u)OOO19 NINOILldO3SOOn 19 Patent Application Publication Feb. 22, 2007 Sheet 18 of 21 US 2007/0042030 A1 Co OC) r 4. S3 - CY) d CMO Z 3.t D CC 2 &gO S. O cN se N1 S. S wim O CN vo C O CN t CP/5u) OOO19 NINOIL31d303SOOnt) Patent Application Publication Feb. 22, 2007 Sheet 19 of 21 US 2007/0042030 A1 33. C d P O v s s cd s O LO Co O s S2 t g Cip?bu) OOO19 NINOIL lO3SOOn 19 Patent Application Publication Feb. 22, 2007 Sheet 20 of 21 US 2007/0042030 A1 o CY) 2 - D CO 4. S H Z CC 2 ?a d O Na 2 1. S2 9 to c O s 2 sCo Ltdis stO (p/6u) OOO19 NINOldO3SOOnt) Patent Application Publication Feb. 22, 2007 Sheet 21 of 21 US 2007/0042030 A1 : sgs Z - O s CO 2 H Z CC Z O s O Na L 1. s (p/6u) OOO19 NINOLTdOSOOnTS) US 2007/0042030 A1 Feb. 22, 2007 PREPARATION FOR THE APPLICATION OF to simply add chemical penetration enhancers to the mixture AGENTS IN MINI-DROPLETS of agent and other molecules; applications to human skin were the only case in which additives were sometimes 0001. The present invention relates to a novel type of applied in advance, in the form of an organic solution. The preparations Suitable for the application of different agents reason for this application form was the current concept for in the form of a minuscule droplet or, in particular, a vesicle the action of penetration enhancers: to date one has studied, consisting of one or a few membrane-like amphiphile discussed, and believed that, in general, any facilitated agent assemblies. These can mediate the transport of agents into penetration is a consequence of skin fluidization, on the one and through a series of natural permeability barriers or hand (Golden et al., (1987) J. Pharm. Sci. 76, 25-28). (This through the constrictions in Such barriers; for example, phenomenon is normally associated with a destruction of the through intact skin or similar organs. The invention further skin Surface and of its protective shield and thus is undes relates to a procedure for the large-scale production of Such ired.) On the other hand, it has been shown that some agents carriers. As a special example, non-invasive application of can permeate through skin in the form of low-molecular antidiabetics is described for the case of insulin. weight complexes with added molecules (Green et al., 0002 The application of various agents is often ham (1988) Int. J. Pharm. 48, 103-111). pered by the presence of barriers with a low permeability to 0006 Methods deviating from the ones already described Such agents. Owing to skin impermeability, for example, have brought little improvement to date. The use of lipoidal many common therapeutic agents must be applied per os or carriers, the liposomes, on intact skin, which has been parenterally (i.v., i.m., i.p.). Intrapulmonary and intranasal theoretically discussed by several authors, was mainly applications of aerosols, the use of rectal formulations, gels aimed at modifying the agent's pharmacokinetics (Patel, for mucous applications, or use of occular formulations are Bioch. Soc. Trans. 609th Meeting, 13, 513-517, 1985, only practicable in certain areas and not for all types of Mezei, M.
Load more

Recommended publications
  • Considerations in Perioperative Assessment of Valproic Acid Coagulopathy Claude Abdallah George Washington University
    Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Anesthesiology and Critical Care Medicine Faculty Anesthesiology and Critical Care Medicine Publications 1-2014 Considerations in perioperative assessment of valproic acid coagulopathy Claude Abdallah George Washington University Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_anesth_facpubs Part of the Anesthesia and Analgesia Commons APA Citation Abdallah, C. (2014). Considerations in perioperative assessment of valproic acid coagulopathy. Journal of Anaesthesiology Clinical Pharmacology, Volume 30, Issue 1 (). http://dx.doi.org/10.4103/0970-9185.125685 This Journal Article is brought to you for free and open access by the Anesthesiology and Critical Care Medicine at Health Sciences Research Commons. It has been accepted for inclusion in Anesthesiology and Critical Care Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact [email protected]. [Downloaded free from http://www.joacp.org on Tuesday, February 25, 2014, IP: 128.164.86.61] || Click here to download free Android application for this journal Revv iew Article Considerations in perioperative assessment of valproic acid coagulopathy Claude Abdallah Department of Anesthesiology, Children’s National Medical Center, The George Washington University Medical Center, NW Washington, DC, USA Abstract Valproic acid (VPA) is one of the widely prescribed antiepileptic drugs in children with multiple indications. VPA-induced coagulopathy may occur and constitute a pharmacological and practical challenge affecting pre-operative evaluation and management of patients receiving VPA therapy. This review summarizes the different studies documenting the incidence, severity and available recommendations related to this adverse effect.
    [Show full text]
  • Module Two the Clinical Neurotoxicology of Chemical Terrorism
    Chemical Agents of Opportunity for Terrorism: TICs & TIMs! Module Two The Clinical Neurotoxicology of Chemical Terrorism Training Support Package 1 Chemical Agents of Opportunity for Terrorism: TICs & TIMs Goals and Objectives • Recognize toxic syndromes that effect the nervous system – Sedation – Convulsions – Hallucinations • Know unique clinical effects of toxins that cause sedation syndromes • List examples of agents of opportunity for each syndrome • Know initial treatment strategy Module Two - The Clinical Neurotoxicology of Chemical Terrorism 2 Chemical Agents of Opportunity for Terrorism: TICs & TIMs Central Nervous System • The CNS is immensely complex – Great target for terrorism • The CNS is central to both our function and our thinking Module Two - The Clinical Neurotoxicology of Chemical Terrorism 3 Chemical Agents of Opportunity for Terrorism: TICs & TIMs The Balance of the Brain • The brain is a fine balance of excitatory and inhibitory influences – Slight alterations in either direction are significant Excitation Inhibition Glutamate Gamma-aminobutyric acid Catecholamines (GABA) Module Two - The Clinical Neurotoxicology of Chemical Terrorism 4 Chemical Agents of Opportunity for Terrorism: TICs & TIMs The Balance of the Brain • In addition, other neurotransmitters influence our mood, our ability to think, remember, etc. Excitation Inhibition Modulators of Thought Processes Serotonin Acetylcholine Module Two - The Clinical Neurotoxicology of Chemical Terrorism 5 Chemical Agents of Opportunity for Terrorism: TICs & TIMs Clinical
    [Show full text]
  • Protabase Record Display Datura Stramonium L
    Protabase Record display www.prota.org Datura stramonium L. Protologue Sp. pl. 1: 179 (1753). Family Solanaceae Chromosome number 2n = 24 Vernacular names Thorn apple, green thorn apple, Jimson weed, Jamestown weed, devil’s apple, devil’s trumpet, stramonium (En). Pomme épineuse, stramoine, datura, feuille du diable, herbe du diable (Fr). Figueira do inferno, pomo espinhoso, erva dos bruxos, palha verde, estramonio (Po). Muranha (Sw). Origin and geographic distribution Datura stramonium is native to the Americas and has been introduced in many tropical, subtropical and even temperate regions. It is a naturalized weed in many African countries, but is probably seriously under-reported. Uses Datura stramonium and Datura metel L. have largely similar medicinal uses throughout the world. The most widely known use of Datura stramonium and of other Datura species is for relieving asthma, cough, tuberculosis and bronchitis by smoking the dried leaves, roots or flowers. ‘Asthma cigarettes’ have been shown to be very effective in some cases, but in other cases they had little or no effect. Cigarettes made with the leaves are also used to treat Parkinson’s disease. A decoction or infusion of leaves is given as a sedative to mental and schizophrenic patients. The leaves are applied as a dressing to cure rheumatic pain, swellings, wounds, gout, burns, ingrown toe-nails, fungal infections, tumours and ulcers. Dried pulverized leaves are dusted on wounds or applied after mixing the powder with fat or Vaseline. In DR Congo pounded fresh root and fresh leaves are soaked in water and the liquid is given in enema as an abortifacient.
    [Show full text]
  • (1982), 24(4), 329—337 Pineal Response to Lithium1
    Indian J. Psychiat. (1982), 24(4), 329—337 PINEAL RESPONSE TO LITHIUM1 S. PARVATHI DEVI* A. VENKOBA RAO> PINEAL FUNCTION AND BEHAVIOUR—A until Crowther demonstrated from his REVIEW autopsy studies that pineal calcification The pineal gland in ma.i is an active had nothing to do with mental derange­ endocrine gland throughout life (Wurtman ment. et al., 1964 ; Tapp & Huxley, 1972 ; Interest in the pineal gland lay dormant Cardinali, 1974 ; Reiter et al., 1975 ; Reiter, and the gland was relegated to be a ves- 1978). It elaborates several hormones with tigeal organ until the endocrine nature precise rhythmicity. The chronobiological of the gland was suggested following des­ aspects of the mammalian pineal gland have criptions of pineal tumours associated with been clearly brought out by Reiler (198!) precocious puberty (Kitay, 1954). The defining the circadian rhythms in indole idea of a special relation of pineal gland to metabolism within the pineal of mammals. mind was revived in reports of experiments The two major classes of pineal hormones— with pineal extracts in the treatment of pineal indoles (melatonin, serotonin and schizophrenia (Becker, 1920 ; Eldered et the tryptophols) and the polypeptides are al., 196U; Kitay & Altschule, 1954). The known to influence several physiological isolation and characterisation of the pineal systems including the central nervous system hormone melatonin was a turning point (Cardinali, 1974 and Anton Tay, 1974). in pineal research (Lerner et al., 1958). The association of pineal gland with be­ Since then the pineal gland has been a haviour and mental illness can be traced to focus of intense scientific enquiry revealing Alexandrian school of thought (Herophilus it to be an endocrine gland capable of c.
    [Show full text]
  • (Antimuscarinic) Drugs?
    © July - August 2018 How well do you know your anticholinergic (antimuscarinic) drugs? nticholinergic drugs, prescribed for a variety of clini- Acal conditions, are amongst the most frequently used prescription drugs in BC (Table 1). Also referred to as “an- timuscarinics,” such drugs specifically block muscarinic receptors for acetylcholine (ACh).1 Muscarinic ACh recep- tors are important in the parasympathetic nervous system that governs heart rate, exocrine glands, smooth muscles, clude drugs whose active metabolites are potent- as well as brain function. In contrast, nicotinic ACh recep- ly antimuscarinic,5 or which often cause typical tors stimulate contraction of striated muscles. This Letter is AC adverse effects such as dry mouth or urinary intended to remind clinicians of commonly used drugs that retention.6 People taking antihistamines, antide- have anticholinergic (AC), or technically, antimuscarinic pressants, antipsychotics, opioids, antimuscarinic properties, and of their potential adverse effects. inhalers, or many other drugs need to know that Beneficial and harmful effects of anticholinergic drugs have blockade of ACh receptors can cause bothersome been known for centuries. In Homer’s Odyssey, the nymph or even dangerous adverse effects (Table 3). pharmacologist Circe utilized central effects of atropinics Subtle and not-so-subtle toxicity in the common plant jimson weed (Datura stramonium) to cause delusions in the crew of Odysseus. Believing they Students often learn the adverse effects of anticho- had been turned into pigs, they could be herded.2 linergics from a mnemonic, e.g.: “Blind as a bat, Sometimes a drug is recommended specifically for its an- mad as a hatter, red as a beet, hot as a hare, dry as ticholinergic potency.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • The Oxytocin/Vasopressin Receptor Family Has at Least Five Members in the Gnathostome Lineage, Including Two Distinct V2 Subtypes
    The oxytocin/vasopressin receptor family has at least five members in the gnathostome lineage, including two distinct V2 subtypes General and Comparative Endocrinology 175(1): 135-143 doi:10.1016/j.ygcen.2011.10.011 Accepted October 20, 2011 E-pub October 28, 2012 Published January 1, 2012 Figshare doi:10.6084/m9.figshare.811860. Shared October 1, 2013 Daniel Ocampo Daza*, Michalina Lewicka¹, Dan Larhammar Department of Neuroscience, Science for Life Laboratory, Uppsala Universitet, Box 593, SE-751 24 Uppsala, Sweden * Corresponding author. E-mail address: [email protected] ¹ Current address: Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden Cite as D. Ocampo Daza, M. Lewicka and D. Larhammar. The oxytocin/vasopressin family has at least five members in the gnathostome lineage, including two distinct V2 subtypes. General and Comparative Endocrinology, 175 (1) (2012) 135-143. This document corresponds to the article as it appeared upon acceptance. You are free to download, print and distribute it for any purposes under a Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/), provided the original work is cited as specified. Errata: The introduction incorrectly states that “the V2 receptor inhibits adenylyl cyclase, thereby reducing the production of cAMP” on page 3. In fact the V2-type vasopressin receptors stimulate adenylyl cyclase and increase the cytosolic cyclic AMP release, see for instance Schöneberg et al., Molecular aspects of vasopressin receptor function, Advances in experimental medicine and biology 449 (1998) 347–58. This mistake was reported in the proofreading phase of pre-publication, but the correction was not carried to the final version of the article.
    [Show full text]
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
    [Show full text]
  • Monographs on Datura Stramonium L
    The School of Pharmaceutical and Biomedical Sciences Pokhara University, P. O. Box 427, Lekhnath, Kaski, NEPAL Monographs on Datura stramonium L Submitted By Bhakta Prasad Gaire Bachelor in Pharmaceutical Sciences (5th Batch) Roll No. 29/2005 [2008] [TYPE THE COMPANY ADDR ESS ] A Plant Monograph on Dhaturo (Datura stramonium L.) Prepared by Bhakta Prasad Gaire Roll No. 29/2005 Submitted to The School of Pharmaceutical and Biomedical Sciences Pokhara University, Dhungepatan-12, Lekhnath, Kaski, NEPAL 2008 ii PREFACE Datura was quite abundantly available in my village (Kuwakot-8, Syangja) since the days of my ancestors. Although it's medicinal uses were not so clear and established at that time, my uncle had a belief that when given along with Gaja, it'll cure diarrhea in cattle. But he was very particular of its use in man and was constantly reminding me not to take it, for it can cause madness. I, on the other hand was very curious and often used to wonder how it looks and what'll actually happen if I take it. This curiosity was also fuelled by other rumours floating around in the village, of the cases of mass hysteria which happened when people took Datura with Panchamrit and Haluwa during Shivaratri and Swasthani Puja. It was in 2052 B.S (I was in class 3 at that time) when an incident happened. One day I came earlier from school (around 2'0 clock), only to find nobody at home. The door was locked and I frantically searched for my mother and sister, but in vain.
    [Show full text]